Zelira Therapeutics Limited

ASX:ZLD Stock Report

Market Cap: AU$6.5m

Zelira Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ZLD?
Owner TypeNumber of SharesOwnership Percentage
Institutions456,6224.02%
Private Companies863,6927.61%
Individual Insiders4,596,70840.5%
General Public5,430,13347.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 23 shareholders own 52.15% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10%
Malik Majeed
1,134,644AU$646.7k0%no data
4.02%
Quincy Street Capital Llc
456,622AU$260.3k0%no data
3.78%
Osagie Imasogie
428,883AU$244.5k0%no data
3.46%
Sharri Rochlin
393,168AU$224.1k0%no data
3.46%
Zoltan Kerekes
393,168AU$224.1k0%no data
3.38%
Jason Peterson
383,725AU$218.7k0%no data
3.37%
Lisa Gray
381,988AU$217.7k0%no data
2.93%
Mera I LLC
332,479AU$189.5k0%no data
2.75%
Muller Ct Pty Ltd
312,126AU$177.9k164%no data
2.71%
Torsten Geers
307,454AU$175.2k0%no data
2.67%
Steve Shapiro
302,571AU$172.5k0%no data
2.22%
Mara Gordon
252,242AU$143.8k0%no data
1.29%
Chanda Macias
146,479AU$83.5k0%no data
1.18%
Mera II LLC
133,372AU$76.0k0%no data
1.16%
Oludare Odumosu
131,766AU$75.1k0%no data
0.76%
Geers Egag LLC
85,715AU$48.9k0%no data
0.67%
Saul Shorr
75,643AU$43.1k0%no data
0.67%
Margaret Shorr
75,642AU$43.1k0%no data
0.46%
Shannon Hexter
51,695AU$29.5k0%no data
0.46%
Daniel Hexter
51,695AU$29.5k0%no data
0.34%
Connie Katz
39,032AU$22.2k0%no data
0.34%
Samuel Katz
39,032AU$22.2k0%no data
0.069%
Timothy Slate
7,881AU$4.5k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 22:06
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zelira Therapeutics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ryan HamptonHannam & Partners (Advisory) LLP